Management of Warfarin Therapy

Introduction to Warfarin Management

The American Heart Association recommends withholding warfarin in patients with supratherapeutic INR (>5.0), during active major bleeding, or for brief periods before high-bleeding-risk procedures, but never as a routine practice for patients with established anticoagulation indications 1, 2

For patients with INR 5.0-9.0 without bleeding, the American Geriatrics Society suggests withholding 1-2 doses of warfarin and monitoring serial INR determinations until the INR falls back into therapeutic range (typically 24-72 hours) 1, 3
The American Geriatrics Society recommends adding oral vitamin K 1-2.5 mg only if the patient has increased bleeding risk factors such as advanced age (>65-75 years), history of bleeding, concomitant antiplatelet drugs, renal failure, or alcohol use 3
For patients with INR >10 without bleeding, the American Geriatrics Society advises withholding warfarin and administering oral vitamin K 5 mg immediately, with INR recheck within 24 hours 3

The European Society of Gastrointestinal Endoscopy recommends immediately withholding warfarin for any patient presenting with major bleeding (clinically overt bleeding with hemoglobin decrease ≥2 g/dL) 2
The European Society of Gastrointestinal Endoscopy suggests administering 4-factor prothrombin complex concentrate (PCC) 25-50 U/kg IV plus vitamin K 5-10 mg by slow IV infusion over 30 minutes for life-threatening bleeding, targeting INR <1.5 2

The American Heart Association recommends withholding warfarin 5 days before elective high-bleeding-risk procedures to allow INR to normalize naturally 1, 5

The American Heart Association advises never withholding warfarin without a specific clinical reason in patients with mechanical heart valves, as the risk of thromboembolism is 10-20% per year without anticoagulation 1
For patients with mechanical mitral valves or prosthetic valves with atrial fibrillation, the European Society of Cardiology recommends that warfarin should not be interrupted without bridging anticoagulation 2, 5

The American Heart Association suggests resuming warfarin at the usual maintenance dose (or 20-30% reduced dose if INR was supratherapeutic) once adequate hemostasis is achieved or INR falls into therapeutic range 2
For high-risk patients requiring bridging, the American Heart Association recommends continuing heparin/LMWH until INR has been therapeutic for at least 48 hours after warfarin restart 1, 6

The American Heart Association advises rechecking INR within 24-48 hours after any intervention for elevated INR to confirm appropriate reduction 4, 7
The American Heart Association recommends continuing monitoring every 24-48 hours until INR stabilizes in therapeutic range 4, 7

The American Heart Association warns against using high-dose vitamin K (≥10 mg) for non-bleeding situations, as this creates warfarin resistance for up to a week and makes re-anticoagulation extremely difficult 4
The American Heart Association advises never withholding warfarin for minor procedures where bleeding is unlikely or inconsequential (dental cleaning, simple dental caries, skin procedures, cataract surgery) 1
The American Geriatrics Society recommends never stopping warfarin without investigating the cause of INR elevation—identify new medications, dietary changes, compliance issues, acute illness, or changes in liver/renal function before resuming therapy 3, 7
The American Heart Association warns against creating a hypercoagulable state by abrupt discontinuation without appropriate bridging in high-risk patients, as markers of thrombosis activation increase with warfarin cessation 1